Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Mehrnoush Naim"'
Autor:
Nancy L. Reinsmoen, Jignesh Patel, Qi Wang, Matthew Rafiei, Lawrence S.C. Czer, Chih-Hung Lai, James Mirocha, Mehrnoush Naim, Kai Cao, Mark Haas, Geraldine Ong, Jon A. Kobashigawa
Publikováno v:
Transplantation. 97:595-601
BACKGROUND De novo donor HLA-specific (dnDSA) and non-HLA antibodies including antiangiotensin type 1 receptor antibodies (AT1R-abs) have been associated with antibody-mediated rejection (AMR) and decreased graft survival as well as cellular-mediated
Autor:
Geraldine Ong, Alfredo Santiago, Mehrnoush Naim, Justin Santos, Rolando Gumatay, Julie Nguyen, Nicola Layne, Qi Wang, Xiaohai Zhang, Maria Manalo, Jasmine Wong, Desiree Magat, Sharon Daroy-Adriatico
Publikováno v:
Human Immunology. 80:117
Publikováno v:
Human Immunology. 79:151
Aim C–C chemokine receptor type 5 (CCR5) is predominantly expressed on T cells, macrophages, and dendritic cells. In addition to the wild type allele, a null allele (CCR5 Delta 32) has a 32-base pair (bp) deletion (CCR5Delta32) in the coding region
Autor:
Xiaohai Zhang, Rolando Gumatay, Justin Santos, Qi Wang, Sharon Daroy-Adriatico, Ernesto J.R. Bustamante, Maria Crouch, Mehrnoush Naim, Alfredo Santiago, Nicola Layne, Maria Manalo, Lesley Cabigon, Geraldine Ong
Publikováno v:
Human Immunology. 79:155
Aim Our approach to transplant highly sensitized patients has been to perform CDC crossmatch (XM) when the results of flow xm are above 200 mean channel shifts (MCS) with donor specific antibodies (DSA). The aim of our study was to determine if the f
Antibody Testing Strategies for Deceased Donor Kidney Transplantation After Immunomodulatory Therapy
Autor:
Chih-Hung Lai, Kai Cao, James Mirocha, Ashley Vo, Mehrnoush Naim, Qi Wang, Stanley C. Jordan, Geraldine Ong, Nancy L. Reinsmoen
Publikováno v:
Transplantation. 92:48-53
BACKGROUND Immunomodulatory protocols including intravenous immunoglobulin/rituximab (IVIG/R) are employed to decrease anti-human leukocyte antigen (HLA) antibody levels for patients broadly sensitized to HLA and increase chances for transplantation
Autor:
Nancy L. Reinsmoen, Mehrnoush Naim, Chih-Hung Lai, Kai Cao, Qi Wang, Stanley C. Jordan, Geraldine Ong, Ashley Vo
Publikováno v:
Transplantation. 86:820-825
BACKGROUND The aims of this study were to determine the level of donor-specific antibody (DSA) that allows for successful transplantation after desensitization with IVIG and rituximab and to identify patients at risk for antibody-mediated rejection (
Autor:
Jon A. Kobashigawa, Jignesh Patel, Xiaohai Zhang, Qi Wang, James Mirocha, Nancy L. Reinsmoen, Geraldine Ong, Chih-Hung Lai, Mehrnoush Naim, Frank Liou, Z. Yu
Publikováno v:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 35(2)
The virtual crossmatch relies on the assignment of unacceptable antigens (UAs) to identify compatible donors. The purpose of our study was to identify an algorithm for assignment of UAs such that a negative complement-dependent cytotoxicity (CDC) cro
Autor:
Mehrnoush Naim, Qi Wang, Rolando Gumatay, Lesley Cabigon, Geraldine Ong, Ernesto J.R. Bustamante, Alfredo Santiago, Xiaohai Zhang, Sharon Daroy-Atriatico
Publikováno v:
Human Immunology. 78:244
Aim Background: Preparation of lymphocytes from living related and deceased donor for flow and CDC crossmatching is labor intensive and occasionally difficult. It is not uncommon that the number of donor cells and cell viability are inadequate, which
Publikováno v:
Human Immunology. 78:221
Aim The Luminex Single Antigen Assay is an integral part of the transplant program to determine patient antibodies. It has an important clinical impact on transplant outcomes. It is suggested that the Luminex single antigen testing on heart transplan
Autor:
Stanely Jordan, Dianne Paredes, Qi Wang, Geraldine Ong, Nancy L. Reinsmoen, Robin Masukawa Alfredo Santiago, Ashley Vo, Rolando Gumatay, Mehrnoush Naim, Janet Yano, Summer Williamson
Publikováno v:
Human Immunology. 76:120
Background The new OPTN/UNOS kidney allocation system (KAS) is designed to expand donor access for highly-HLA sensitized patients (HS). Our approach to transplanting the HS patients (PTS) awaiting deceased donor (DD) transplants (TXP) is to assign un